Navigation Links
Dendreon Reports Third Quarter 2008 Financial Results
Date:11/7/2008

SEATTLE, Nov. 7 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended September 30, 2008. Revenue for the third quarter of 2008 was $26,000 compared to $112,000 for the quarter ended September 30, 2007. Revenue for the nine months ended September 30, 2008 was $83,000 compared to $715,000 for the nine months ended September 30, 2007.

Dendreon's total operating expenses for the third quarter of 2008 were $17.3 million compared to $19.8 million in 2007. Dendreon's total operating expenses for the nine months ended September 30, 2008 were $55.1 million compared to $75.2 million for the same period in 2007.

The net loss for the quarter ended September 30, 2008 was $26.8 million, or $0.29 per share, compared to a net loss of $19.2 million, or $0.23 per share, for the quarter ended September 30, 2007. The net loss for the nine months ended September 30, 2008 was $62.8 million, or $0.71 per share, compared to $72.3 million, or $0.88 per share for the nine months ended September 30, 2007. Included in our net loss for the three and nine months ended September 30, 2008 was a non-cash charge of $9.1 million and $6.8 million, respectively, to other expense. This represents an increase in the fair value of the warrants issued in connection with our April 3, 2008 common stock offering, which has been recorded as a liability.

Cash, cash equivalents and short-term and long-term investments at September 30, 2008 totaled $106.6 million compared to $120.6 million at December 31, 2007. Additionally, subsequent to September 30, 2008, the Company received net proceeds of $19.8 million relating to a draw down on the Company's equity line of credit with Azimuth Opportunity Ltd.

Recent Highlights:

* Completed the planned interim analysis of the Phase 3, randomized,

double-blind, placebo-controlled IMPACT (IMmunotherapy for Prostate

AdenoCarcinoma Treatment, also know
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
2. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
5. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
6. Dendreon Reports First Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
8. Dendreon Announces Closing of Registered Direct Offering
9. Dendreon Announces $47 Million Registered Direct Offering
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... immune system identifies the transplanted organ as foreign tissue ... cells, the immune cells that mediate rejection, must first ... to migrate to the transplanted organ. In this issue ... Lakkis and colleagues at the University of Pittsburgh used ... is not required for migration. Instead, these cells must ...
(Date:5/17/2013)... New interactive learning forums ... leaders of the medical device industry at the ... expo, from June 18-20 in Philadelphia ... ) , These all-new MedTech ... practical presentations and implementable solutions on the most ...
(Date:5/17/2013)... Miami, FL (PRWEB) May 17, 2013 Men’s ... at La-roche Posay ) and has been known ... itself. Although some men may be far from puberty, other ... be clogging pores, causing breakouts, and threatening skin with unsightly ... with advice from Men’s Health on how to ...
(Date:5/17/2013)... Tooth decay is an epidemic in American children with 50% ... World Health Organization says that worldwide, 60–90% of ... are the long-term effects of this transmissible infection? , ... oral bacterial imbalance and serious systemic issues like heart disease. ... also 100% preventable? Answer: there has been no way to ...
Breaking Biology Technology:MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... Expand Versatility of DelSite cGMP Polymer, ... (Pink Sheets: CARN) today announced its wholly-owned,subsidiary, ... rights license agreement with a biotechnology company ... DelSite,s,high-molecular-weight anionic polysaccharide which is produced under ...
... 19 /Xinhua-PRNewswire/ -- Shanghai Century (Amex:,SHA), a special ... Co., Ltd (Kelun), China,s largest producer of,intravenous (IV) ... highlights with respect to the consolidated results of,operations ... entity,(Kelun Group) for the first half of 2007. ...
... PARSIPPANY, N.J., Sept. 19 Over 20 new ... Biotech Competitive Intelligence &,Business Analysis" conference in two ... standard for pharmaceutical CI, Business Analysis, and Market,Forecasting ... gather on,October 1-2 to attend the meeting. Competition ...
Cached Biology Technology:Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines 2Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines 3Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 2Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 3Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 4Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 5New Competitive Intelligence Speakers Spark Interest in Pharmaceutical Conference on October 1-2 in NJ 2
(Date:5/17/2013)... Ill. An international team of ... structure and cell movement inside a living frog embryo ... a new method to advance biological research and the ... Northwestern University and the Karlsruher Institut fr Technologie in ... the U.S. Department of Energy,s Argonne National Laboratory, released ...
(Date:5/16/2013)... MARC (Maximizing Access to Research Careers) Program has ... for Developmental Biology (SDB) 72nd Annual Meeting in ... are meant to promote the entry of students, ... mainstream of the basic science community and to ... SDB 2013 Annual Meeting. , Awards are given ...
(Date:5/16/2013)... University scientists have shown a gene involved in neurodegenerative ... function of the circadian clock. , In a ... the gene, called Ataxin-2, keeps the clock responsible for ... gene, the rhythm of the fruit fly,s sleep-wake cycle ... difficult for the fly. , The discovery is ...
Breaking Biology News(10 mins):New X-ray method shows how frog embryos could help thwart disease 2Gene involved in neurodegeneration keeps clock running 2
... in the September issue of the Journal of Lipid ... a role in the rising rate of diabetes, especially in ... is the primary mechanism of inheritance; kids get half their ... just starting to understand additional kinds of inheritance like metabolic ...
... a group of University of Oklahoma researchers began studying ... has plagued the energy industry for decades, they did ... capable of converting hydrocarbons into natural gas. ... hydrocarbon metabolismcan be used to stimulate methane gas production ...
... received a $3.2 million grant from the National ... and mathematical disciplines to stem cell research. In ... experts in fields such as cell and molecular ... breakthroughs from the biology lab into practical and ...
Cached Biology News:OU researchers isolate microorganisms that convert hydrocarbons to natural gas 2OU researchers isolate microorganisms that convert hydrocarbons to natural gas 3$3.2M for Rutgers to apply biology, engineering, physical sciences toward stem cells 2$3.2M for Rutgers to apply biology, engineering, physical sciences toward stem cells 3
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
pETDuet-1 is designed for the coexpression of two target genes....
Human IL-29/IFN-lambda 1 Biotinylated Affinity Purified PAb...
Mouse Laminin-1 MAb (Clone AL-3)...
Biology Products: